There are 2949 resources available
Welcome
Presenter: Bettina Ryll
Session: MSD - New approaches, old barriers: Will cancer patients get access to the combinations and early treatments they need?
Resources:
Webcast
The innovative early treatment landscape
Presenter: Nils Wilking
Session: MSD - New approaches, old barriers: Will cancer patients get access to the combinations and early treatments they need?
Resources:
Webcast
Access, availability, and uptake of combination therapies in Europe
Presenter: Tim Wilsdon
Session: MSD - New approaches, old barriers: Will cancer patients get access to the combinations and early treatments they need?
Resources:
Webcast
Panel discussion moderated by Bettina Ryll
Presenter: Deepak Khanna
Session: MSD - New approaches, old barriers: Will cancer patients get access to the combinations and early treatments they need?
Resources:
Webcast
Welcome and introductions
Presenter: Arndt Vogel
Session: F. Hoffmann-La Roche - Integrating cancer immunotherapy combinations into HCC practice: Duos, data and decisions
Resources:
Webcast
Tracking the recent advances within the field of unresectable HCC
Presenter: David Pinato
Session: F. Hoffmann-La Roche - Integrating cancer immunotherapy combinations into HCC practice: Duos, data and decisions
Resources:
Webcast
Reviewing the latest phase III efficacy data for unresectable HCC
Presenter: Andrew Zhu
Session: F. Hoffmann-La Roche - Integrating cancer immunotherapy combinations into HCC practice: Duos, data and decisions
Resources:
Webcast
Exploring key safety data for cancer immunotherapy combinations
Presenter: Philippe Merle
Session: F. Hoffmann-La Roche - Integrating cancer immunotherapy combinations into HCC practice: Duos, data and decisions
Resources:
Webcast
Moving into the clinic: how will these data inform our clinical decisions?
Presenter: Arndt Vogel
Session: F. Hoffmann-La Roche - Integrating cancer immunotherapy combinations into HCC practice: Duos, data and decisions
Resources:
Webcast
Panel discussion
Presenter: Philippe Merle
Session: F. Hoffmann-La Roche - Integrating cancer immunotherapy combinations into HCC practice: Duos, data and decisions
Resources:
Webcast